VIVUS let down with FDA Bulletin Committee’s uphold on QNEXA someone is concerned rotundity treatment
VIVUS, Inc. (Nasdaq: VVUS) today announced that the Endocrinologic and Metabolic Drugs Hortatory Council of the U.S. Commons and Upper Direction (FDA) voted against the following examine: "Based on the widespread at ones fingertips text, do you think the all-embracing benefit-risk assessment of PHEN/TPM (QNEXA) is favorable to weather its rubber-stamp allowing for regarding the treatment of plumpness in individuals with a BMI > 30 kg/m2 or > 27 kg/m2 with weight-related co-morbidities?" The three co-morbidities included hypertension, diabetes and dyslipidemia.
The certify from the Endocrinologic and Metabolic Drugs Parnetical Board is a approbation. The FDA on recant the Committee’s blessing into rumination during its re-examination of the popular relevancy and will-power contribute to a ascertaining. The FDA may or may not practise the Committee’s urging.
"We conscious of the Counselling Committee’s acceptance of chubbiness as a important haleness catastrophe, and the challenges associated with the treatment of this malady," stated Leland Wilson, chief head honcho administrator, VIVUS. "We are frustrated with the Admonitory Committee’s opinion. While the settled voter was tiny, and we are encouraged that the Board recognized the efficacy demonstrated in the QNEXA clinical trials, we determination urge a exercise closely with the FDA supreme up to our October 28, 2010 PDUFA girl to direct the labeling and sanctuary questions raised during today’s proceedings. We carcass committed to patients living with paunchiness and weight-related disease."
AUTHOR VIVUS, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
